CJC-1295 / Ipamorelin Blend

This blend combines two peptides that stimulate growth hormone release through distinct and complementary receptor pathways. CJC-1295 is a modified version of Growth Hormone Releasing Hormone (GHRH), specifically the first 29 amino acids (GHRH 1-29), with amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). Its molecular weight is approximately 3367 Da without the Drug Affinity Complex (DAC). Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) with a molecular weight of approximately 711.85 Da that acts as a selective ghrelin receptor (GHSR-1a) agonist.

The two peptides work through fundamentally different receptor systems. CJC-1295 binds to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, amplifying the amplitude of natural GH pulses. It does not create new pulses but rather makes existing pulses larger. The modified amino acids at key positions extend its plasma half-life from the 7-10 minutes of native GHRH to approximately 30 minutes for CJC-1295 without DAC, or 6-8 days for the DAC-conjugated version that covalently binds to serum albumin. Ipamorelin, meanwhile, binds to GHSR-1a on the same somatotroph cells but through a completely independent signaling cascade. It mimics the action of ghrelin, the endogenous hunger hormone, triggering GH release via IP3/DAG second messenger pathways rather than the cAMP pathway used by GHRH.

Clinical research on these peptides individually is substantial. A Phase 2 study of CJC-1295 with DAC (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006, N=21 healthy subjects) demonstrated sustained IGF-1 elevation of 200-300% above baseline for 6-11 days following a single subcutaneous injection. GH levels remained elevated for the same period with maintained pulsatility. Ipamorelin was studied in a Phase 2 trial for post-operative ileus (Lasseter et al., published in the Journal of Clinical Pharmacology, 2008, N=114) and demonstrated dose-dependent GH release with no statistically significant increases in cortisol, prolactin, ACTH, or aldosterone at any dose tested, a selectivity profile unmatched by any other GH secretagogue peptide including GHRP-2, GHRP-6, or hexarelin.

Pharmacokinetically, the two peptides complement each other in timing. Without DAC, CJC-1295 has a half-life of approximately 30 minutes, producing a GH pulse that peaks within 30-60 minutes and returns to baseline within 2-3 hours. Ipamorelin has a half-life of approximately 2 hours, with peak GH release at 40 minutes post-injection. When co-administered, the overlapping but slightly offset kinetics produce a broader, more sustained GH elevation than either peptide alone. Both peptides are cleared hepatically and renally. Neither peptide accumulates with repeated dosing, and both maintain efficacy without tolerance development over study periods of up to 12 weeks.

The lyophilized blend should be stored at -20C (stable for 24+ months). Reconstitute with 1-2 mL of bacteriostatic water. Both peptides are stable across a pH range of 5.0-8.0 and are fully compatible in solution. Store the reconstituted blend at 2-8C and use within 28 days. Protect from light. CJC-1295 is the more fragile component and is susceptible to oxidation; the vial headspace should be minimized after each withdrawal.

In published research protocols, the combination is typically administered subcutaneously, with most studies using doses of 100-300 mcg of each peptide per administration. Dosing is commonly performed in the evening before sleep to coincide with the natural nocturnal GH surge, or 2-3 times daily (morning, post-exercise, pre-sleep) in protocols targeting maximal GH output. Research protocols typically run 8-12 weeks with 5 days on, 2 days off schedules to prevent receptor desensitization, though some protocols use continuous daily dosing without apparent tolerance.

The safety profile of this combination is among the most favorable of any GH secretagogue stack. Ipamorelin's selectivity means the combination does not cause the hunger spikes (via GHSR activation in the hypothalamus) seen with GHRP-6, the cortisol and prolactin elevations seen with GHRP-2 and hexarelin, or the water retention and insulin resistance seen with exogenous GH. The most commonly reported side effects in published research are transient flushing at the injection site and occasional mild headache, both of which typically resolve within the first week. There is no published evidence of pituitary desensitization or suppression of endogenous GH production with this combination when used at standard research doses.